# Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction

> **NCT07044700** · — · NOT_YET_RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 5000 (estimated)

## Conditions studied

- Heart Failure of Reduced Ejection Fraction (HFrEF)

## Interventions

- **DRUG:** Jardiance
- **DRUG:** non-SGLT2 inhibitors

## Key facts

- **NCT ID:** NCT07044700
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2028-01-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 5000 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07044700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07044700, "Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07044700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*